Requirements for chronic back pain disease management program outlined in Germany

27

May 2019

Statutory health insured patients with chronic back pain can benefit in the future from a structured treatment program (Disease Management Program, DMP): The Federal Joint Committee (G-BA) outlined on the 18th of April the substantive requirements for the new DMP. These include, for example, the eligibility criteria, the individual treatment planning, and the coordination of the different specialists involved in the treatment process within the therapeutic approach. The statutory health insurance funds can conclude contracts with physicians and / or hospitals for the practical implementation of the DMP after the decision has come into force.

Enrollment in the DMP will be possible for the patients with chronic (more than 12 weeks) pain in the cross-sectional area of the back, significant activity restrictions, and lingering needs in treatment. If there are specific causes for the back pain, such as vertebral fractures, rheumatic diseases or a tumor in the spinal column area, enrolment in the DMP will not be possible, as the treatment of the causative disease(s) is in the foreground. The attending physician will be obliged to check whether the inclusion and exclusion criteria for enrollment in the chronic back pain DMP are met.

The individually indicated therapeutic measures will be planned during the doctor-patient interview - pain intensity and activity restriction of the patient as well as the successes achieved in the course of treatment are to be considered here. It is obligatory for every patient enrolled in the DMP to be informed about the decisive, positive role of physical activity and to be motivated to undergo physical training. The chronic back pain DMP also will include basic and drug-related recommendations for pain medications.

The scientific basis of the new DMP is built with the use of the information presented in “Systematic guideline search and evaluation as well as extraction of relevant recommendations for a chronic back pain DMP” of the Institute for Quality and Efficiency in Health Care (IQWiG), published in November 2015. IQWiG was assigned this task by the G-BA in August 2014.

The G-BA is now submitting the resolution to the Federal Ministry of Health (BMG) for examination. After non-objection, the requirements for the chronic back pain DMP and the corresponding documentation will come into force on the first day of the quarter following the publication in the Federal Gazette.

The DMP requirements for the following chronic diseases are also currently being developed:

  • Depression
  • Osteoporosis
  • Rheumatoid arthritis

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more